A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder,Journal of Child and Adolescent Psychopharmacology

当前位置： X-MOL 学术 › J. Child Adolesc. Psychopharmacol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder
Journal of Child and Adolescent Psychopharmacology ( IF 1.5 ) Pub Date : 2022-03-15 , DOI: 10.1089/cap.2021.0138
Ann C Childress ₁ , Eric Lloyd ₂ , Steven A Johnson ₃ , Lhanoo Gunawardhana ₂ , Valerie Arnold ₄

Affiliation

Objective: To evaluate the long-term safety and tolerability of lisdexamfetamine dimesylate (LDX) in preschool-aged children (4–5 years of age inclusive) diagnosed with attention-deficit/hyperactivity disorder (ADHD).

中文翻译：

Lisdexamfetamine Dimesylate 在 4-5 岁注意力缺陷/多动障碍儿童中的长期、开放标签安全性和耐受性研究

目的：评估被诊断为注意力缺陷/多动障碍 (ADHD) 的学龄前儿童（包括 4-5 岁）使用二甲磺酸地塞地塞米特胺 (LDX) 的长期安全性和耐受性。

更新日期：2022-03-15

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11